

Thousands of lives could be saved using tranexamic acid for patients with bleeding trauma

A systematic review of randomised controlled trials of the effectiveness of tranexamic acid (TXA), which reduces clot breakdown, in patients with bleeding after severe injury shows that this inexpensive drug could save tens of thousands of lives a year.¹ The review found that TXA reduces the risk of death in injured patients with severe bleeding by about 10% compared with giving no treatment. This would equate to more than 70 000 lives a year if treatment were rolled out world wide (see table 1). On the basis of these new findings, the British military have already started using TXA to treat soldiers wounded in battle in Afghanistan,² and TXA is now being incorporated into civilian trauma treatment protocols around the world.³

Most of the data in the review came from the international CRASH-2 trial,⁴ which recruited 20 211 patients with bleeding trauma from some 40 countries world wide and showed that TXA significantly reduces mortality with no apparent increase in the risk of vascular occlusive events. Because the CRASH-2

results are based on large numbers of patients, with both blunt and penetrating trauma, and from many different countries, they can be generalised widely. Given the high quality of evidence for the benefits of this drug, the authors recommend that TXA is considered for use in every patient with severe bleeding from traumatic injury.

Studies are now underway to see if TXA can reduce deaths from post partum haemorrhage⁵ (which kills about 100 000 women each year, most of whom live in developing countries) and traumatic intracranial bleeding which is a major cause of death and disability. Further interactive material on the topic is available through the *Cochrane Journal Club*.⁶

The review mentioned here is published on the *Cochrane Library* (<http://www.thecochranelibrary.com/>) website. For further information on this or other Cochrane reviews contact Emma Sydenham, managing editor of the Cochrane Injuries Group (emma.sydenham@lshtm.ac.uk).

Emma Sydenham

Correspondence to Emma Sydenham, Cochrane Injuries Group, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK; emma.sydenham@lshtm.ac.uk

Competing interests None.

Provenance and peer review Not commissioned; internally peer reviewed.

Injury Prevention 2011; ■:1. doi:10.1136/injuryprev-2011-040059

Table 1 Deaths that could be avoided by the administration of tranexamic acid (TXA) to patients with bleeding trauma (10 countries with the highest numbers of avoided deaths shown)¹

Country	Trauma deaths	Haemorrhage deaths	Deaths averted with TXA
India	714 730	85 768	12 865
China	667 277	80 073	12 011
Indonesia	279 499	33 534	5030
Russia	246 836	29 620	4443
Brazil	122 953	14 754	2206
USA	122 529	14 703	2206
Iraq	99 968	11 996	1799
Nigeria	87 811	10 537	1581
Bangladesh	76 938	9233	1385
DRC	73 579	8829	1324
World	4 100 645	492 077	73 812

Copyright Cochrane Collaboration, reproduced with permission. Trauma and haemorrhage death estimates taken from the WHO Global Burden of Disease Study: http://www.who.int/healthinfo/global_burden_disease/en/.

REFERENCES

1. **Roberts I**, Shakur H, Ker K, *et al*. Antifibrinolytic drugs for acute traumatic injury. *Cochrane Database Syst Rev* 2011;(1):CD004896.
2. **Sadler C**. Injured soldiers in Afghanistan saved by blood clotting drug. *British Forces News* 20 Jan 2011. <http://www.bfbs.com/news/afghanistan/injured-soldiers-afghanistan-saved-blood-clotting-drug-43115.html> (accessed 31 Mar 2011).
3. **World Health Organization, Department of Reproductive Health and Research**. *Who Guidelines for the Management of Postpartum Haemorrhage and Retained Placenta*. Geneva, Switzerland: WHO Press, 2009.
4. **Shakur H**, Roberts I, Bautista R, *et al*; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. *Lancet* 2010;**376**:23–32.
5. **Shakur H**, Elbourne D, Gülmezoglu M, *et al*. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. *Trials* 2010;**11**:40.
6. Antifibrinolytic drugs for acute traumatic injury. *Cochrane Journal Club Issue 18*. <http://www.cochranejournalclub.com/antifibrinolytic-drugs-acute-traumatic-injury-clinical/> (accessed 31 Mar 2011).